🇺🇸 FDA
Pipeline program

Ex-vivo expanded allogeneic γδ T cells

IIT2025056

Phase 1 mab active

Quick answer

Ex-vivo expanded allogeneic γδ T cells for AML (Acute Myelogenous Leukemia) is a Phase 1 program (mab) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
China SXT Pharmaceuticals
Indication
AML (Acute Myelogenous Leukemia)
Phase
Phase 1
Modality
mab
Status
active

Clinical trials